Is Inducible Nitric Oxide Synthase (iNOS) Promising as a New Target Against Pulmonary Hypertension?

Pulmonary hypertension (PH) is a progressive disease characterized by elevated blood pressure in the pulmonary arteries, associated also with inflammation and oxidative stress. Inducible nitric oxide synthase (iNOS) is one of the key mediators of inflammation and immune system activation. Although p...

Full description

Saved in:
Bibliographic Details
Main Authors: Piotr Ryszkiewicz, Eberhard Schlicker, Barbara Malinowska
Format: Article
Language:English
Published: MDPI AG 2025-03-01
Series:Antioxidants
Subjects:
Online Access:https://www.mdpi.com/2076-3921/14/4/377
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850156193740226560
author Piotr Ryszkiewicz
Eberhard Schlicker
Barbara Malinowska
author_facet Piotr Ryszkiewicz
Eberhard Schlicker
Barbara Malinowska
author_sort Piotr Ryszkiewicz
collection DOAJ
description Pulmonary hypertension (PH) is a progressive disease characterized by elevated blood pressure in the pulmonary arteries, associated also with inflammation and oxidative stress. Inducible nitric oxide synthase (iNOS) is one of the key mediators of inflammation and immune system activation. Although preclinical studies mostly suggest a detrimental role of iNOS overactivation in PH, there is a lack of exhaustive analyses and summaries. Therefore, this literature overview aims to fill this gap. The involvement of iNOS in the pathogenesis of the four main clinical groups of PH is discussed to assess whether targeting iNOS could be a promising way to treat PH. iNOS expression patterns in the organs primarily affected by PH are analyzed both in animals and in humans. Consequently, the effectiveness of pharmacological iNOS inhibition and/or iNOS gene deletion is discussed and compared, also with reference to the activity of constitutive NOS isoforms, particularly endothelial NOS (eNOS). Overall, our overview suggests that selective iNOS inhibitors could be considered as a novel treatment strategy for PH, as decreases in right ventricular and pulmonary artery pressure, the alleviation of ventricular hypertrophy, and improvements of pulmonary and cardiac function were observed, among others. Nevertheless, further research efforts in this area are needed.
format Article
id doaj-art-1e513febce5a4ada8ae7b01c9a51223a
institution OA Journals
issn 2076-3921
language English
publishDate 2025-03-01
publisher MDPI AG
record_format Article
series Antioxidants
spelling doaj-art-1e513febce5a4ada8ae7b01c9a51223a2025-08-20T02:24:39ZengMDPI AGAntioxidants2076-39212025-03-0114437710.3390/antiox14040377Is Inducible Nitric Oxide Synthase (iNOS) Promising as a New Target Against Pulmonary Hypertension?Piotr Ryszkiewicz0Eberhard Schlicker1Barbara Malinowska2Department of Experimental Physiology and Pathophysiology, Medical University of Bialystok, Mickiewicz Str. 2A, 15-222 Bialystok, PolandDepartment of Pharmacology and Toxicology, University of Bonn, Venusberg Campus 1, 53127 Bonn, GermanyDepartment of Experimental Physiology and Pathophysiology, Medical University of Bialystok, Mickiewicz Str. 2A, 15-222 Bialystok, PolandPulmonary hypertension (PH) is a progressive disease characterized by elevated blood pressure in the pulmonary arteries, associated also with inflammation and oxidative stress. Inducible nitric oxide synthase (iNOS) is one of the key mediators of inflammation and immune system activation. Although preclinical studies mostly suggest a detrimental role of iNOS overactivation in PH, there is a lack of exhaustive analyses and summaries. Therefore, this literature overview aims to fill this gap. The involvement of iNOS in the pathogenesis of the four main clinical groups of PH is discussed to assess whether targeting iNOS could be a promising way to treat PH. iNOS expression patterns in the organs primarily affected by PH are analyzed both in animals and in humans. Consequently, the effectiveness of pharmacological iNOS inhibition and/or iNOS gene deletion is discussed and compared, also with reference to the activity of constitutive NOS isoforms, particularly endothelial NOS (eNOS). Overall, our overview suggests that selective iNOS inhibitors could be considered as a novel treatment strategy for PH, as decreases in right ventricular and pulmonary artery pressure, the alleviation of ventricular hypertrophy, and improvements of pulmonary and cardiac function were observed, among others. Nevertheless, further research efforts in this area are needed.https://www.mdpi.com/2076-3921/14/4/377nitric oxideinducible nitric oxide synthasenitrosative stresspulmonary hypertensioncardiovascular systempulmonary arterial hypertension
spellingShingle Piotr Ryszkiewicz
Eberhard Schlicker
Barbara Malinowska
Is Inducible Nitric Oxide Synthase (iNOS) Promising as a New Target Against Pulmonary Hypertension?
Antioxidants
nitric oxide
inducible nitric oxide synthase
nitrosative stress
pulmonary hypertension
cardiovascular system
pulmonary arterial hypertension
title Is Inducible Nitric Oxide Synthase (iNOS) Promising as a New Target Against Pulmonary Hypertension?
title_full Is Inducible Nitric Oxide Synthase (iNOS) Promising as a New Target Against Pulmonary Hypertension?
title_fullStr Is Inducible Nitric Oxide Synthase (iNOS) Promising as a New Target Against Pulmonary Hypertension?
title_full_unstemmed Is Inducible Nitric Oxide Synthase (iNOS) Promising as a New Target Against Pulmonary Hypertension?
title_short Is Inducible Nitric Oxide Synthase (iNOS) Promising as a New Target Against Pulmonary Hypertension?
title_sort is inducible nitric oxide synthase inos promising as a new target against pulmonary hypertension
topic nitric oxide
inducible nitric oxide synthase
nitrosative stress
pulmonary hypertension
cardiovascular system
pulmonary arterial hypertension
url https://www.mdpi.com/2076-3921/14/4/377
work_keys_str_mv AT piotrryszkiewicz isinduciblenitricoxidesynthaseinospromisingasanewtargetagainstpulmonaryhypertension
AT eberhardschlicker isinduciblenitricoxidesynthaseinospromisingasanewtargetagainstpulmonaryhypertension
AT barbaramalinowska isinduciblenitricoxidesynthaseinospromisingasanewtargetagainstpulmonaryhypertension